PDE5A and erectile dysfunction: Only one study reached moderate certainty.<h4>Discussion/conclusion</h4>Current evidence suggests that genetic polymorphisms related to nitric oxide signaling, vascular regulation, and PDE5 inhibitor pharmacodynamics are associated with variability in erectile dysfunction risk and treatment response.